SAMSUNG PHARMACEUTICAL Co., Ltd.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 89
- Market Cap
- -
- Website
- http://www.sspharm.co.kr
GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD)
Phase 3
Not yet recruiting
- Conditions
- Moderate to Severe Alzheimer's Disease
- Interventions
- Drug: GV1001 PlaceboDrug: GV1001 1.12mg
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Samsung Pharmaceutical Co., Ltd.
- Target Recruit Count
- 750
- Registration Number
- NCT05303701
A Phase III Study to Assess the Efficacy and Safety of GV1001-Gem/Cap vs Gem/Cap in Pancreatic Cancer Patients
- First Posted Date
- 2016-08-03
- Last Posted Date
- 2016-11-22
- Lead Sponsor
- Samsung Pharmaceutical Co., Ltd.
- Target Recruit Count
- 148
- Registration Number
- NCT02854072
- Locations
- 🇰🇷
National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of
🇰🇷Gangnam Severance Hospital, Seoul, Korea, Republic of
🇰🇷Jeju National University Hospital, Jeju-si, Jeju-do, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath